title: Multicenter study on the immunogenicity and safety of two recombinant vaccines against hepatitis B.
abstract: The immunogenicity and safety of a new recombinant hepatitis B vaccine from the Instituto Butantan (Butang) were evaluated in a multicenter, double-blind, prospective equivalence study in three centers in Brazil. Engerix B was the standard vaccine. A total of 3937 subjects were recruited and 2754 (70%) met all protocol criteria at the end of the study. All the subjects were considered healthy and denied having received hepatitis B vaccine before the study. Study subjects who adhered to the protocol were newborn infants (566), children 1 to 10 years old (484), adolescents from 11 to 19 years (740), adults from 20 to 30 years (568), and adults from 31 to 40 years (396). Vaccine was administered in three doses on the schedule 0, 1, and 6 months (newborn infants, adolescents, and adults) or 0, 1, and 7 months (children). Vaccine dose was intramuscular 10 microg (infants, children, and adolescents) or 20 microg (adults). Percent seroprotection (assumed when anti-HBs titers were > 10 mIU/ml) and geometric mean titer (mIU/ml) were: newborn infants, 93.7% and 351.1 (Butang) and 97.5% and 1530.6 (Engerix B); children, 100% and 3600.0 (Butang) and 97.7% and 2753.1 (Engerix B); adolescents, 95.1% and 746.3 (Butang) and 96% and 1284.3 (Engerix B); adults 20-30 years old, 91.8% and 453.5 (Butang) and 95.5% and 1369.0 (Engerix B); and adults 31-40 years old, 79.8% and 122.7 (Butang) and 92.4% and 686.2 (Engerix B). There were no severe adverse events following either vaccine. The study concluded that Butang was equivalent to Engerix B in children, and less immunogenic but acceptable for use in newborn infants, adolescents, and young adults.
authors.affiliation: Comitê Técnico Assessor em Imunizações, Secretaria de Vigilância em Saúde, Ministério da Saúde, Av. Erico Veríssimo 430-12, 22621-180 Rio de Janeiro, Brazil. reinaldomm@ig.com.br
authors.forename: Reinaldo Menezes
authors.initials: RM
authors.lastname: Martins
authors.forename: Gilberta
authors.initials: G
authors.lastname: Bensabath
authors.forename: Luiz Claudio
authors.initials: LC
authors.lastname: Arraes
authors.forename: Maria de Lourdes Aguiar
authors.initials: Mde L
authors.lastname: Oliveira
authors.forename: Juliana Custódio
authors.initials: JC
authors.lastname: Miguel
authors.forename: Glayse Glayde
authors.initials: GG
authors.lastname: Barbosa
authors.forename: Luiz Antonio Bastos
authors.initials: LA
authors.lastname: Camacho
mesh_terms: D000293:Adolescent; D000328:Adult; D001938:Brazil; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D005260:Female; D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000097:blood*; D006511:Hepatitis B Antigens / Q000276:immunology*; D017325:Hepatitis B Vaccines / Q000009:adverse effects / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D011446:Prospective Studies; D012044:Regression Analysis; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000276:immunology
chemical_list: D006510:Hepatitis B Antibodies; D006511:Hepatitis B Antigens; D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic